alexa Jia-Long Fang | Shanghai Medical University

Annals of Infections and Antibiotics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Jia-Long Fang

Jia-Long Fang Jia-Long Fang
Division of Biochemical Toxicology
National Center for Toxicological Research
3900 NCTR Road,
HFT-110 Jefferson,
AR 72079
P.R. China
Biography

Dr. Fang is a Research Biologist at the Division of Biochemical Toxicology, National Center for Toxicological Research/FDA. Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has been the principal investigator on many approved NCTR protocols that address the biological mechanisms underlying the toxicities of drugs and chemicals. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.

Dr. Fang received a Bachelor’s degree in Public Health in 1985 from Shanghai Medical University and a Master’s degree in Toxicology in 1990 from Chinese Academy of Preventive Medicine in China. In 1997, Dr. Fang received his Ph.D. in Molecular Epidemiology from the renowned Karolinska Institute in Stockholm, Sweden. He joined the NCTR/FDA as an ORISE Postdoctoral Fellow in 1997 and rejoined the NCTR/FDA as a Staff Fellow in 2004. Dr. Fang is author/co-author of 56 publications including peer-reviewed articles and/or scientific reports.

Research Interest

Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has designed, developed, and executed in vitro and in vivo research investigations that address the biological mechanisms underlying the toxicities of drugs and chemicals. Throughout his career at NCTR, Dr. Fang’s research has been focused on the biological mechanisms of action underlying the toxicity of chemicals regulated by, or of interest to, the FDA, such as ethanol, urethane, tolvaptan, and antiretroviral drugs, including zidovudine, lamivudine, and nevirapine. More recently, Dr. Fang has been leading a research team to investigate the toxicities of topically applied triclosan. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords